Skip to main content

Advertisement

Table 1 Summary of rheumatic patients included in the frequency study

From: CD25brightCD4+regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease

Diagnosis, subdiagnosis Number Sex (F/M) Age (years) Median (range) CD25brightCD4+ in PB (%) Median (range) CD25brightCD4+ in SF (%) Median (range) Fold increase, SF/PBa Median (range)b
Spondyloarthropathies 36 20/16 46 (21–83) 0.7 (0.2–2.9) 2.7 (0.4–9.1) 4.8 (0.7–20.7)***
   PsA 26 14/12 50 (24–83) 0.6 (0.2–2.9) 2.6 (1.0–9.1) 4.7 (0.9–20.7)
   SpAc 10 6/4 33 (21–58) 1.2 (0.4–2.4) 3.4 (0.4–6.8) 5.0 (0.7–17.6)
   JIA 21 18/3 30 (18–50) 0.4 (0.1–1.8) 3.7 (0.3–6.7) 6.7 (3.1–16.3)***
Rheumatoid arthritis 135 107/28 57 (22–85) 0.7 (0.04–2.9) 2.3 (0.2–19.9) 3.7 (0.4–56.8)***
   RF+ 109 88/21 57 (25–81) 0.7 (0.04–2.9) 2.3 (0.3–19.9) 3.5 (0.4–56.8)
   RF- 26 19/7 56 (22–85) 0.9 (0.2–2.4) 2.4 (0.7–19.7) 4.3 (0.6–19.9)
Healthy controls 29 25/4 51 (23–63) 1.2 (0.3–2.4) na na
  1. JIA, juvenile idiopathic arthritis; na, not analyzed; PB, peripheral blood, SF, synovial fluid. aCalculated as percentage of CD25brightCD4+ cells in SF divided by percentage of CD25brightCD4+ cells in PB. bA significant enrichment of CD25brightCD4+ T cells in SF over that in PB was found: ***P < 0.0001. cAnkylosing spondylitis and undifferentiated spondyloarthropathies. Excluded are patients with reactive arthritis and gastrointestinal inflammation.